ClearOne's Cortigent merger clears key hurdle with stockholder consent, while $10M–$15M financing and governance terms come into focus
CLRO has more than doubled off its 52-week low of $2.71 on light trading volume (0.1× avg).
Summary
ClearOne's merger with Cortigent advances as majority stockholders approve the 12.5M-share issuance and change of control. A concurrent $10M–$15M financing and new incentive plan are detailed, setting the stage for a reverse merger that will leave existing holders with a small minority stake in a pre-revenue neurotech venture.
Key Events · M&A and Partnerships · CLRO
-
Stockholder Consent Secured
Holders of 61.3% of ClearOne's shares approved the issuance of 12.5M shares to Vivani Medical for the Cortigent acquisition, satisfying Nasdaq's 20% issuance and change-of-control rules.
-
Massive Dilution for Existing Holders
Post-merger, existing ClearOne shareholders will own just 16.69% of the combined company (before any financing), while Vivani will hold 77.98% and advisors 5.33%.
-
$10M–$15M Financing to Fund Operations
ClearOne will raise $10M–$15M via units of one share and one $10 warrant (6-month term) immediately before or at closing; proceeds are critical given Cortigent's going-concern warning and $3.8M working capital deficit.
-
New Incentive Plan Approved
A 2026 Omnibus Incentive Plan with 2.5M shares was approved, with up to 1.4M options to be granted to Cortigent-affiliated individuals at closing.
Analysis · CLRO · Manufacturing
Written consent from holders of 61.3% of ClearOne's shares has been obtained to issue 12.5 million shares to Vivani Medical for the acquisition of Cortigent, a neurotechnology developer. This step satisfies Nasdaq's 20% issuance and change-of-control rules, removing a significant obstacle. The filing also details a concurrent $10M–$15M unit offering—each unit comprising one share and a $10 warrant—to fund the combined company, alongside a new 2.5M-share incentive plan. Post-close, Vivani will own approximately 78% of ClearOne, which will be renamed Cortigent Holdings and trade under 'CRGT'. For existing shareholders, the deal is a double-edged sword: it transforms a distressed shell with a going-concern warning into a clinical-stage medical device company, but at the cost of extreme dilution, leaving them with roughly 17% before any financing. The merger represents a high-stakes pivot that hands control to Vivani and bets on early-stage neurotech assets with no revenue and substantial capital needs.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLRO was trading at $7.02 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $2.71 to $16.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.